|Download document||Draft best practice guidance for pilot European Medicines Agency health technology assessment parallel scientific advice procedures|
|Status||draft: consultation open|
|Consultation start date||08/05/2014|
|Consultation end date||14/07/2014|
|Email address for submissions|
As the first step to market access, a new medicine requires a marketing authorisation from a medicines regulatory agency. The second step prior to enabling patient access to a new therapeutic option increasingly involves the assessment of its usefulness to the healthcare system that lies with a payer or healthcare-guidance organisation, and the Health Technology Assessment Bodies (HTABs) that advise them.